Coping with COVID-19

We are certainly living in unprecedented times, and we need to be vigilant while continuing to provide medical care for our patients. On that front, I am implementing policies that mirror the ones that our teams are using at Yale. Due to the COVID – 19 pandemic and the recommendations of the CDC and the American College of Physicians, actions have been implemented to effect social distancing and allow us to care for patients in as safe a manner as possible.

Patient Appointments

Deferrals: Patients with no immediate clinical needs whose care can be rescheduled for at least 30 days into the future.
Visits for Patients on Medications or with ongoing challenges: Patients who have clinical reasons to be seen will be asked to come in for their visit as long as they are well and screen “Coronavirus Negative”. This means: NO recent fever, NO active cough or significant respiratory symptoms, and NO known exposure to someone who is positive for COVID-19.
Tele-health visits: Patients who have a scheduled appointment but have had recent illness or exposures, and are having issues that require a medical or behavioral health follow-up visit, should arrange this type of visit by calling ahead. Most insurance companies are allowing these visits given the current circumstances.

Updates to Visit Policy

Until further notice, only parent/caregivers may accompany patients who have an appointment. In order to keep the waiting rooms empty and cleaned between patients, siblings are not permitted to accompany the patient to outpatient visits. Thank you for your understanding.

Additionally, all books, art supplies, games, etc have been removed from our common areas and offices, so please plan accordingly for your child when you come.

Thank you for your understanding as we try to provide essential medical services in the safest way possible. If you have questions, do not hesitate to call our office or email us at sunflowerdevelopmentalpeds@gmail.com.

COVID-19 Information Page

National Drug Supply

The mission of Drug Enforcement Administrations (DEA), Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.

During this National Emergency the Diversion Control Division will continue to work with our Federal partners, DEA registrants, and their representative association to assure that there is an adequate supply of controlled substances in the United States. The DEA will also work to assure that patients will have access to controlled substances.

DEA is unaware of any shortages of controlled substances at this time. DEA is working with the Food and Drug Administration (FDA) on monitoring the supply of controlled substance availability during the COVID-19 Pandemic. Please see the link to the FDA’s website www.fda.gov for more information on FDA’s response.

If you are a patient who uses controlled substances, you should know that DEA works closely with all registrants to ensure consistent supply and assist with appropriate emergency response. Our mission is to ensure an adequate, uninterrupted supply of controlled substances, within a closed system of distribution.

DEA is in touch with controlled substance manufacturers, distributors, and importers, and is unaware of any drug shortages at this time. If you are a DEA registered manufacturer, distributor, or importer of controlled substances and are having issues with your supply chain, please contact your local field office, or email DEA at: Natural.Disaster@usdoj.gov